Primary urethral solitary plasmacytoma is a very rare variant of extramedullary plasmacytoma. In total, only 9 cases have been reported so far. Patients were treated either by surgery or by external radiation therapy. Here, we report on a 22-year-old man, initially presenting with a palpable induration at the penis, intermittent dysuria and haematospermia, which was due to histologically confirmed solitary urethral kappa-restricted plasmacytoma. The patient subsequently underwent percutaneous and endo-urethral high-dose-rate brachytherapy with a total dose of 42 Gy applied in 14 fractions. Besides an uncomplicated urinary tract infection and hyperpigmentation of the penis, the patient tolerated the radiotherapy well and is still free of disease after 15 months follow-up.

Keywords:
Brachytherapy, Extramedullary plasmacytoma, Urethra
1.
Alexiou C, Kau RJ, Dietzfelbinger H, et al: Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer 1999;85:2305-2314.
2.
Alcorn SR, Gocke CD, Woodard CA, Tran PT: Solitary plasmacytoma of the penile urethra treated with primary radiotherapy. J Clin Oncol 2014;32:e95-e97.
3.
Witjes JA, De Vries JD, Schaafsma HE, et al: Extramedullary plasmacytoma of the urethra: a case report. J Urol 1991;145:826-828.
4.
Mark JA, Pais VM, Chong FK: Plasmacytoma of the urethra treated with transurethral resection and radiotherapy. J Urol 1990;143:1010-1011.
5.
Fernández Jiménez I, de Diego García E, Sandoval González F: [Nephrogenic adenoma of the urethra. Report of a case]. Cir Pediatr 2003;16:203-204.
6.
Krishna Kumar G, Malcomson R, Chandran H: Nephrogenic adenoma of the urethra presenting as hematuria. Indian J Surg 2014;76:228-229.
7.
Ford TF, Watson GM, Cameron KM: Adenomatous metaplasia (nephrogenic adenoma) of urothelium. An analysis of 70 cases. Br J Urol 1985;57:427-433.
8.
Weber DM: Solitary bone and extramedullary plasmacytoma. Hematology AM Soc Hematol Educ Program 2005;2005:373-376.
9.
Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R: Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:1063-1067.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.